Theravance Biopharma (NASDAQ:TBPH) Rating Lowered to Hold at StockNews.com

Theravance Biopharma (NASDAQ:TBPH – Get Rating) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

A number of other research firms also recently issued reports on TBPH. SVB Leerink boosted their price objective on shares of Theravance Biopharma from $12.00 to $14.00 and gave the company an “outperform” rating in a report on Thursday, November 17th. HC Wainwright boosted their target price on shares of Theravance Biopharma from $12.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, November 8th.

Theravance Biopharma Trading Up 0.8 %

NASDAQ TBPH traded up $0.09 during trading on Tuesday, reaching $10.99. The company’s stock had a trading volume of 279,762 shares, compared to its average volume of 500,051. The firm has a market capitalization of $740.35 million, a price-to-earnings ratio of 0.98 and a beta of 0.51. Theravance Biopharma has a 12 month low of $7.53 and a 12 month high of $11.83. The firm has a 50 day moving average price of $10.92 and a 200 day moving average price of $10.09.

Theravance Biopharma (NASDAQ:TBPH – Get Rating) last posted its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. The business had revenue of $12.45 million during the quarter, compared to the consensus estimate of $19.09 million. On average, equities analysts forecast that Theravance Biopharma will post -0.88 EPS for the current fiscal year.

Insider Activity

In other news, CEO Rick E. Winningham sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 14th. The shares were sold at an average price of $11.19, for a total value of $559,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,350,797 shares in the company, valued at approximately $15,115,418.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors have recently added to or reduced their stakes in the stock. Palliser Capital UK Ltd acquired a new position in Theravance Biopharma during the 4th quarter worth approximately $1,089,000. Bank of New York Mellon Corp increased its position in Theravance Biopharma by 12.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 205,470 shares of the biopharmaceutical company’s stock worth $2,084,000 after purchasing an additional 23,555 shares in the last quarter. Weiss Asset Management LP increased its position in Theravance Biopharma by 19.6% during the 3rd quarter. Weiss Asset Management LP now owns 7,457,060 shares of the biopharmaceutical company’s stock worth $75,615,000 after purchasing an additional 1,219,622 shares in the last quarter. Two Sigma Advisers LP acquired a new position in Theravance Biopharma during the 3rd quarter worth approximately $7,064,000. Finally, Two Sigma Investments LP acquired a new position in Theravance Biopharma during the 3rd quarter worth approximately $6,620,000.

Theravance Biopharma Company Profile

(Get Rating)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.